You are here: Home pathway Area of law pathway Tegison

Defective Drugs Lawyers and Attorneys Legal Help


Etretinate for Psoriasis Caused Serious Birth Defects in Pregnant Women Affects Bone Growth in Children

Tegison is also known as Etretinate and is used to treat severe cases of psoriasis. This medicine was withdrawn from the U.S. market in March 1998 and the Canadian market in January 1996.

Etretinate has caused serious birth defects in the newborns of pregnant women who use it during pregnancy, do not use this medicine if pregnant. Etretinate has been linked to increased fluid pressure on the brain and hepatitis, which can cause discoloration such as yellow eyes and skin, vision changes, darkening of the urine, fatigue, headache, stomach pain, nausea and vomiting.

Etretinate should not be used to treat psoriasis in young children as it interferes with normal bone growth, and because children exhibit higher sensitivity to the side effects of Tegison.